Core Viewpoint - Vaxcyte Inc. (NASDAQ:PCVX) is identified as a promising mid-cap healthcare stock with significant upside potential, supported by positive analyst ratings and upcoming clinical trials [1][4]. Group 1: Analyst Ratings and Price Targets - BTIG analyst Thomas Shrader has reiterated a Buy rating for Vaxcyte Inc. with a target price of $85, indicating an upside of over 83% from current levels [1]. - Consensus ratings show all 7 analysts have assigned Buy ratings, with a median 1-year price target of $100.80 per share, representing a potential upside of 117.2% [4]. Group 2: Clinical Trials and Product Development - Positive results from Phase 2 trials for the VAX-31 vaccine are expected to support the critical Phase 3 trials, which have a robust design and stringent success criteria [2]. - The target market for VAX-31 includes individuals aged 50 to 65, suggesting strong potential for market adoption [3]. - Vaxcyte Inc. focuses on developing next-generation vaccines using innovative synthetic methods and advanced chemistry to enhance immunological benefits [5].

As filed with the Securities and Exchange Commission on August 29, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMUNON, INC. (Exact name of registrant as specified in its charter) (I.R.S. Employer Identification No.) 997 Lenox Drive, Suite 100 Lawrenceville, New Jersey 08648 (609) 896-9100 (Address, including zip code, and telephone number, including area code, of Registrant's principal exe ...